カテゴリー： Market Monitor Global, 世界, 医療/バイオ

神経線維腫症1型の世界市場見通し2023年-2029年

◆英語タイトル：Neurofibromatosis Type 1 Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5802）

◆商品コード：MMG23JU5802
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：76
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Neurofibromatosis Type 1 Market 調査レポートは次の情報を含め、グローバルにおけるの神経線維腫症1型市場規模と予測を収録しています。・世界の神経線維腫症1型市場：売上、2018年-2023年、2024年-2029年
・世界の神経線維腫症1型市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の神経線維腫症1型市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「10mg」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

神経線維腫症1型のグローバル主要企業は、AstraZeneca、 Merckなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、神経線維腫症1型のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の神経線維腫症1型市場：タイプ別、2018年-2023年、2024年-2029年
世界の神経線維腫症1型市場：タイプ別市場シェア、2022年
・10mg、25mg

世界の神経線維腫症1型市場：用途別、2018年-2023年、2024年-2029年
世界の神経線維腫症1型市場：用途別市場シェア、2022年
・病院、診療所、その他

世界の神経線維腫症1型市場：地域・国別、2018年-2023年、2024年-2029年
世界の神経線維腫症1型市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における神経線維腫症1型のグローバル売上、2018年-2023年
・主要企業における神経線維腫症1型のグローバル売上シェア、2022年
・主要企業における神経線維腫症1型のグローバル販売量、2018年-2023年
・主要企業における神経線維腫症1型のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
AstraZeneca、 Merck

*************************************************************

・調査・分析レポートの概要
神経線維腫症1型市場の定義
市場セグメント
世界の神経線維腫症1型市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の神経線維腫症1型市場規模
世界の神経線維腫症1型市場規模：2022年 VS 2029年
世界の神経線維腫症1型市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの神経線維腫症1型の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の神経線維腫症1型製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：10mg、25mg
神経線維腫症1型のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
神経線維腫症1型の用途別グローバル売上・予測

・地域別市場分析
地域別神経線維腫症1型市場規模 2022年と2029年
地域別神経線維腫症1型売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
AstraZeneca、 Merck
...

NF1 is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals. It is caused by a spontaneous or inherited mutation in the NF1 gene and is associated with many symptoms, including soft lumps on and under the skin (cutaneous neurofibromas) and skin pigmentation (so-called ‘café au lait’ spots) and, in 30-50% of patients, tumours develop on the nerve sheaths (plexiform neurofibromas).
This report aims to provide a comprehensive presentation of the global market for Neurofibromatosis Type 1, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurofibromatosis Type 1. This report contains market size and forecasts of Neurofibromatosis Type 1 in global, including the following market information:
Global Neurofibromatosis Type 1 Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Neurofibromatosis Type 1 Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Neurofibromatosis Type 1 companies in 2022 (%)
The global Neurofibromatosis Type 1 market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
10 mg Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Neurofibromatosis Type 1 include AstraZeneca and Merck etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurofibromatosis Type 1 manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neurofibromatosis Type 1 Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neurofibromatosis Type 1 Market Segment Percentages, by Type, 2022 (%)
10 mg
25 mg
Global Neurofibromatosis Type 1 Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neurofibromatosis Type 1 Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Neurofibromatosis Type 1 Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neurofibromatosis Type 1 Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neurofibromatosis Type 1 revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Neurofibromatosis Type 1 revenues share in global market, 2022 (%)
Key companies Neurofibromatosis Type 1 sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Neurofibromatosis Type 1 sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Merck
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neurofibromatosis Type 1, market overview.
Chapter 2: Global Neurofibromatosis Type 1 market size in revenue and volume.
Chapter 3: Detailed analysis of Neurofibromatosis Type 1 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neurofibromatosis Type 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Neurofibromatosis Type 1 capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Neurofibromatosis Type 1 Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neurofibromatosis Type 1 Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neurofibromatosis Type 1 Overall Market Size
2.1 Global Neurofibromatosis Type 1 Market Size: 2022 VS 2029
2.2 Global Neurofibromatosis Type 1 Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Neurofibromatosis Type 1 Sales: 2018-2029
3 Company Landscape
3.1 Top Neurofibromatosis Type 1 Players in Global Market
3.2 Top Global Neurofibromatosis Type 1 Companies Ranked by Revenue
3.3 Global Neurofibromatosis Type 1 Revenue by Companies
3.4 Global Neurofibromatosis Type 1 Sales by Companies
3.5 Global Neurofibromatosis Type 1 Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Neurofibromatosis Type 1 Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Neurofibromatosis Type 1 Product Type
3.8 Tier 1, Tier 2 and Tier 3 Neurofibromatosis Type 1 Players in Global Market
3.8.1 List of Global Tier 1 Neurofibromatosis Type 1 Companies
3.8.2 List of Global Tier 2 and Tier 3 Neurofibromatosis Type 1 Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Neurofibromatosis Type 1 Market Size Markets, 2022 & 2029
4.1.2 10 mg
4.1.3 25 mg
4.2 By Type – Global Neurofibromatosis Type 1 Revenue & Forecasts
4.2.1 By Type – Global Neurofibromatosis Type 1 Revenue, 2018-2023
4.2.2 By Type – Global Neurofibromatosis Type 1 Revenue, 2024-2029
4.2.3 By Type – Global Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
4.3 By Type – Global Neurofibromatosis Type 1 Sales & Forecasts
4.3.1 By Type – Global Neurofibromatosis Type 1 Sales, 2018-2023
4.3.2 By Type – Global Neurofibromatosis Type 1 Sales, 2024-2029
4.3.3 By Type – Global Neurofibromatosis Type 1 Sales Market Share, 2018-2029
4.4 By Type – Global Neurofibromatosis Type 1 Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Neurofibromatosis Type 1 Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application – Global Neurofibromatosis Type 1 Revenue & Forecasts
5.2.1 By Application – Global Neurofibromatosis Type 1 Revenue, 2018-2023
5.2.2 By Application – Global Neurofibromatosis Type 1 Revenue, 2024-2029
5.2.3 By Application – Global Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
5.3 By Application – Global Neurofibromatosis Type 1 Sales & Forecasts
5.3.1 By Application – Global Neurofibromatosis Type 1 Sales, 2018-2023
5.3.2 By Application – Global Neurofibromatosis Type 1 Sales, 2024-2029
5.3.3 By Application – Global Neurofibromatosis Type 1 Sales Market Share, 2018-2029
5.4 By Application – Global Neurofibromatosis Type 1 Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Neurofibromatosis Type 1 Market Size, 2022 & 2029
6.2 By Region – Global Neurofibromatosis Type 1 Revenue & Forecasts
6.2.1 By Region – Global Neurofibromatosis Type 1 Revenue, 2018-2023
6.2.2 By Region – Global Neurofibromatosis Type 1 Revenue, 2024-2029
6.2.3 By Region – Global Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
6.3 By Region – Global Neurofibromatosis Type 1 Sales & Forecasts
6.3.1 By Region – Global Neurofibromatosis Type 1 Sales, 2018-2023
6.3.2 By Region – Global Neurofibromatosis Type 1 Sales, 2024-2029
6.3.3 By Region – Global Neurofibromatosis Type 1 Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Neurofibromatosis Type 1 Revenue, 2018-2029
6.4.2 By Country – North America Neurofibromatosis Type 1 Sales, 2018-2029
6.4.3 US Neurofibromatosis Type 1 Market Size, 2018-2029
6.4.4 Canada Neurofibromatosis Type 1 Market Size, 2018-2029
6.4.5 Mexico Neurofibromatosis Type 1 Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Neurofibromatosis Type 1 Revenue, 2018-2029
6.5.2 By Country – Europe Neurofibromatosis Type 1 Sales, 2018-2029
6.5.3 Germany Neurofibromatosis Type 1 Market Size, 2018-2029
6.5.4 France Neurofibromatosis Type 1 Market Size, 2018-2029
6.5.5 U.K. Neurofibromatosis Type 1 Market Size, 2018-2029
6.5.6 Italy Neurofibromatosis Type 1 Market Size, 2018-2029
6.5.7 Russia Neurofibromatosis Type 1 Market Size, 2018-2029
6.5.8 Nordic Countries Neurofibromatosis Type 1 Market Size, 2018-2029
6.5.9 Benelux Neurofibromatosis Type 1 Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Neurofibromatosis Type 1 Revenue, 2018-2029
6.6.2 By Region – Asia Neurofibromatosis Type 1 Sales, 2018-2029
6.6.3 China Neurofibromatosis Type 1 Market Size, 2018-2029
6.6.4 Japan Neurofibromatosis Type 1 Market Size, 2018-2029
6.6.5 South Korea Neurofibromatosis Type 1 Market Size, 2018-2029
6.6.6 Southeast Asia Neurofibromatosis Type 1 Market Size, 2018-2029
6.6.7 India Neurofibromatosis Type 1 Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Neurofibromatosis Type 1 Revenue, 2018-2029
6.7.2 By Country – South America Neurofibromatosis Type 1 Sales, 2018-2029
6.7.3 Brazil Neurofibromatosis Type 1 Market Size, 2018-2029
6.7.4 Argentina Neurofibromatosis Type 1 Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Neurofibromatosis Type 1 Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Neurofibromatosis Type 1 Sales, 2018-2029
6.8.3 Turkey Neurofibromatosis Type 1 Market Size, 2018-2029
6.8.4 Israel Neurofibromatosis Type 1 Market Size, 2018-2029
6.8.5 Saudi Arabia Neurofibromatosis Type 1 Market Size, 2018-2029
6.8.6 UAE Neurofibromatosis Type 1 Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Neurofibromatosis Type 1 Major Product Offerings
7.1.4 AstraZeneca Neurofibromatosis Type 1 Sales and Revenue in Global (2018-2023)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Merck
7.2.1 Merck Company Summary
7.2.2 Merck Business Overview
7.2.3 Merck Neurofibromatosis Type 1 Major Product Offerings
7.2.4 Merck Neurofibromatosis Type 1 Sales and Revenue in Global (2018-2023)
7.2.5 Merck Key News & Latest Developments
8 Global Neurofibromatosis Type 1 Production Capacity, Analysis
8.1 Global Neurofibromatosis Type 1 Production Capacity, 2018-2029
8.2 Neurofibromatosis Type 1 Production Capacity of Key Manufacturers in Global Market
8.3 Global Neurofibromatosis Type 1 Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Neurofibromatosis Type 1 Supply Chain Analysis
10.1 Neurofibromatosis Type 1 Industry Value Chain
10.2 Neurofibromatosis Type 1 Upstream Market
10.3 Neurofibromatosis Type 1 Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Neurofibromatosis Type 1 Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Neurofibromatosis Type 1 in Global Market
Table 2. Top Neurofibromatosis Type 1 Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Neurofibromatosis Type 1 Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Neurofibromatosis Type 1 Revenue Share by Companies, 2018-2023
Table 5. Global Neurofibromatosis Type 1 Sales by Companies, (K Units), 2018-2023
Table 6. Global Neurofibromatosis Type 1 Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Neurofibromatosis Type 1 Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Neurofibromatosis Type 1 Product Type
Table 9. List of Global Tier 1 Neurofibromatosis Type 1 Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neurofibromatosis Type 1 Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Neurofibromatosis Type 1 Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Neurofibromatosis Type 1 Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Neurofibromatosis Type 1 Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Neurofibromatosis Type 1 Sales (K Units), 2018-2023
Table 15. By Type - Global Neurofibromatosis Type 1 Sales (K Units), 2024-2029
Table 16. By Application – Global Neurofibromatosis Type 1 Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Neurofibromatosis Type 1 Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Neurofibromatosis Type 1 Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Neurofibromatosis Type 1 Sales (K Units), 2018-2023
Table 20. By Application - Global Neurofibromatosis Type 1 Sales (K Units), 2024-2029
Table 21. By Region – Global Neurofibromatosis Type 1 Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Neurofibromatosis Type 1 Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Neurofibromatosis Type 1 Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Neurofibromatosis Type 1 Sales (K Units), 2018-2023
Table 25. By Region - Global Neurofibromatosis Type 1 Sales (K Units), 2024-2029
Table 26. By Country - North America Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Neurofibromatosis Type 1 Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Neurofibromatosis Type 1 Sales, (K Units), 2018-2023
Table 29. By Country - North America Neurofibromatosis Type 1 Sales, (K Units), 2024-2029
Table 30. By Country - Europe Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Neurofibromatosis Type 1 Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Neurofibromatosis Type 1 Sales, (K Units), 2018-2023
Table 33. By Country - Europe Neurofibromatosis Type 1 Sales, (K Units), 2024-2029
Table 34. By Region - Asia Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Neurofibromatosis Type 1 Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Neurofibromatosis Type 1 Sales, (K Units), 2018-2023
Table 37. By Region - Asia Neurofibromatosis Type 1 Sales, (K Units), 2024-2029
Table 38. By Country - South America Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Neurofibromatosis Type 1 Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Neurofibromatosis Type 1 Sales, (K Units), 2018-2023
Table 41. By Country - South America Neurofibromatosis Type 1 Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Neurofibromatosis Type 1 Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Neurofibromatosis Type 1 Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Neurofibromatosis Type 1 Sales, (K Units), 2024-2029
Table 46. AstraZeneca Company Summary
Table 47. AstraZeneca Neurofibromatosis Type 1 Product Offerings
Table 48. AstraZeneca Neurofibromatosis Type 1 Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. AstraZeneca Key News & Latest Developments
Table 50. Merck Company Summary
Table 51. Merck Neurofibromatosis Type 1 Product Offerings
Table 52. Merck Neurofibromatosis Type 1 Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Merck Key News & Latest Developments
Table 54. Neurofibromatosis Type 1 Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 55. Global Neurofibromatosis Type 1 Capacity Market Share of Key Manufacturers, 2021-2023
Table 56. Global Neurofibromatosis Type 1 Production by Region, 2018-2023 (K Units)
Table 57. Global Neurofibromatosis Type 1 Production by Region, 2024-2029 (K Units)
Table 58. Neurofibromatosis Type 1 Market Opportunities & Trends in Global Market
Table 59. Neurofibromatosis Type 1 Market Drivers in Global Market
Table 60. Neurofibromatosis Type 1 Market Restraints in Global Market
Table 61. Neurofibromatosis Type 1 Raw Materials
Table 62. Neurofibromatosis Type 1 Raw Materials Suppliers in Global Market
Table 63. Typical Neurofibromatosis Type 1 Downstream
Table 64. Neurofibromatosis Type 1 Downstream Clients in Global Market
Table 65. Neurofibromatosis Type 1 Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Neurofibromatosis Type 1 Segment by Type in 2022
Figure 2. Neurofibromatosis Type 1 Segment by Application in 2022
Figure 3. Global Neurofibromatosis Type 1 Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Neurofibromatosis Type 1 Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Neurofibromatosis Type 1 Revenue, 2018-2029 (US$, Mn)
Figure 7. Neurofibromatosis Type 1 Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Neurofibromatosis Type 1 Revenue in 2022
Figure 9. By Type - Global Neurofibromatosis Type 1 Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
Figure 11. By Type - Global Neurofibromatosis Type 1 Sales Market Share, 2018-2029
Figure 12. By Type - Global Neurofibromatosis Type 1 Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Neurofibromatosis Type 1 Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
Figure 15. By Application - Global Neurofibromatosis Type 1 Sales Market Share, 2018-2029
Figure 16. By Application - Global Neurofibromatosis Type 1 Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Neurofibromatosis Type 1 Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Neurofibromatosis Type 1 Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
Figure 20. By Region - Global Neurofibromatosis Type 1 Sales Market Share, 2018-2029
Figure 21. By Country - North America Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
Figure 22. By Country - North America Neurofibromatosis Type 1 Sales Market Share, 2018-2029
Figure 23. US Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Neurofibromatosis Type 1 Sales Market Share, 2018-2029
Figure 28. Germany Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 29. France Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Neurofibromatosis Type 1 Sales Market Share, 2018-2029
Figure 37. China Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 41. India Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
Figure 43. By Country - South America Neurofibromatosis Type 1 Sales Market Share, 2018-2029
Figure 44. Brazil Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Neurofibromatosis Type 1 Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Neurofibromatosis Type 1 Sales Market Share, 2018-2029
Figure 48. Turkey Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Neurofibromatosis Type 1 Revenue, (US$, Mn), 2018-2029
Figure 52. Global Neurofibromatosis Type 1 Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Neurofibromatosis Type 1 by Region, 2022 VS 2029
Figure 54. Neurofibromatosis Type 1 Industry Value Chain
Figure 55. Marketing Channels

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 神経線維腫症1型の世界市場見通し2023年-2029年(Neurofibromatosis Type 1 Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

神経線維腫症1型の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp